Non-coding RNA therapeutics in cardiovascular disease and risk factors: Systematic review

• Main Authors: Meity Ardiana, Meity, Asiyah Nurul Fadila, -, Zakirah Zuhra, -, Nabilla Merdika Kusuma, -, Made Edgard Surya Erlangga Rurus, -, Delvac Oceandy, -
• Format: Article PeerReviewed
• Language: English; English; Indonesian; English
• Published: Elsevier 2023
• Subjects: R5-920 Medicine (General)
• Online Access: https://repository.unair.ac.id/128444/1/20.%20Non-coding%20RNA%20therapeutics.pdf; https://repository.unair.ac.id/128444/3/20.%20Non-coding%20RNA%20therapeutics-1-48.pdf; https://repository.unair.ac.id/128444/11/18.%20karil.pdf; https://repository.unair.ac.id/128444/12/18.%20korespondensi.pdf; https://repository.unair.ac.id/128444/; https://www.sciencedirect.com/science/article/pii/S2468054023000367?via%3Dihub; https://doi.org/10.1016/j.ncrna.2023.06.002
• Institution: Universitas Airlangga

Abstract At present, RNA-based therapy which includes therapies using non-coding RNAs (ncRNAs), antisense oligonucleotides (ASOs), and aptamers are gaining widespread attention as possible ways to target genes in various cardiovascular diseases (CVDs), thereby serving as a promising therapeutic approach for CVDs and risk factors management. However, data are primarily in an early stage. A systematic review was carried out using literature from several databases (Pubmed, Cochrane, Scopus, and DOAJR) following the PRISMA guidelines. Of the 64 articles reviewed, 39 papers were included in this review with three main types of RNAs: aptamers, antisense oligonucleotides (ASOs), and small-interfering RNA (siRNA). All studies were human clinical trials. RNA-based therapies were demonstrated to be efficacious in treating various CVDs and controlling cardiovascular risk factors. They are generally safe and well-tolerated. However, data are still in the early stage and warrant further investigation.